Literature DB >> 7814023

Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease.

T Lehtimäki1, T Pirttilä, P D Mehta, H M Wisniewski, H Frey, T Nikkari.   

Abstract

The apoE phenotype of 83 patients with probable Alzheimer's disease (AD) and of 164 non-demented controls was determined by isoelectric focusing and Western blotting. The proportion of the epsilon 4 allele was 0.548 in AD and 0.202 in controls (P < 0.0001). The effect was seen in both early-onset and late-onset AD patients. The risk of AD in epsilon 4 homozygotes was 18-fold greater than in individuals without the epsilon 4 allele. ApoE concentrations were measured in serum and cerebrospinal fluid (CSF) from a subgroup of patients with AD (n = 72) and controls (n = 84) by a sandwich enzyme-linked immunosorbent assay. Although serum apoE concentrations were lower in individuals with the epsilon 4 allele than in those without the epsilon 4 allele, CSF apoE concentrations did not vary in different phenotype groups. However, CSF apoE levels were lower in AD patients than in controls. We conclude that the inheritance of the epsilon 4 allele of apoE is a risk factor for AD in the Finnish population.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7814023     DOI: 10.1007/bf00225071

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  30 in total

1.  Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage.

Authors:  M A Pericak-Vance; J L Bebout; P C Gaskell; L H Yamaoka; W Y Hung; M J Alberts; A P Walker; R J Bartlett; C A Haynes; K A Welsh
Journal:  Am J Hum Genet       Date:  1991-06       Impact factor: 11.025

2.  Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene.

Authors:  M C Chartier-Harlin; F Crawford; H Houlden; A Warren; D Hughes; L Fidani; A Goate; M Rossor; P Roques; J Hardy
Journal:  Nature       Date:  1991-10-31       Impact factor: 49.962

3.  Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism.

Authors:  E Boerwinkle; G Utermann
Journal:  Am J Hum Genet       Date:  1988-01       Impact factor: 11.025

4.  The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease.

Authors:  R Mayeux; Y Stern; R Ottman; T K Tatemichi; M X Tang; G Maestre; C Ngai; B Tycko; H Ginsberg
Journal:  Ann Neurol       Date:  1993-11       Impact factor: 10.422

5.  Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid.

Authors:  J Carlsson; V W Armstrong; H Reiber; K Felgenhauer; D Seidel
Journal:  Clin Chim Acta       Date:  1991-02-15       Impact factor: 3.786

6.  Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease.

Authors:  T Brousseau; S Legrain; C Berr; V Gourlet; O Vidal; P Amouyel
Journal:  Neurology       Date:  1994-02       Impact factor: 9.910

7.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Authors:  W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

8.  The genetic defect causing familial Alzheimer's disease maps on chromosome 21.

Authors:  P H St George-Hyslop; R E Tanzi; R J Polinsky; J L Haines; L Nee; P C Watkins; R H Myers; R G Feldman; D Pollen; D Drachman
Journal:  Science       Date:  1987-02-20       Impact factor: 47.728

9.  Confirmation of association between the e4 allele of apolipoprotein E and Alzheimer's disease.

Authors:  M Liddell; J Williams; A Bayer; F Kaiser; M Owen
Journal:  J Med Genet       Date:  1994-03       Impact factor: 6.318

10.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

View more
  25 in total

1.  Polymorphism of apolipoproteine E in relation with Alzheimer and vascular dementia.

Authors:  Zuzana Gdovinová; Viera Habalová; Zuzana Novosadová
Journal:  Cell Mol Neurobiol       Date:  2006-06-07       Impact factor: 5.046

2.  Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?

Authors:  J-C Lambert; D Mann; F Richard; J Tian; J Shi; U Thaker; S Merrot; J Harris; B Frigard; T Iwatsubo; C Lendon; P Amouyel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

3.  CSF Apo-E levels associate with cognitive decline and MRI changes.

Authors:  Jon B Toledo; Xiao Da; Michael W Weiner; David A Wolk; Sharon X Xie; Steven E Arnold; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-01-03       Impact factor: 17.088

Review 4.  Biomarkers of Alzheimer disease in plasma.

Authors:  Michael C Irizarry
Journal:  NeuroRx       Date:  2004-04

Review 5.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

6.  Plasma alkaline phosphatase is elevated in Alzheimer's disease and inversely correlates with cognitive function.

Authors:  Katherine Ab Kellett; Jonathan Williams; Emma Rlc Vardy; A David Smith; Nigel M Hooper
Journal:  Int J Mol Epidemiol Genet       Date:  2011-02-10

7.  The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease.

Authors:  M Landén; A Thorsell; A Wallin; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

8.  Both targeted mass spectrometry and flow sorting analysis methods detected the decreased serum apolipoprotein E level in Alzheimer's disease patients.

Authors:  Sun-Ho Han; Jun Seok Kim; Youngju Lee; Heesun Choi; Jong-Won Kim; Duk Lyul Na; Eun Gyeong Yang; Myeong-Hee Yu; Daehee Hwang; Cheolju Lee; Inhee Mook-Jung
Journal:  Mol Cell Proteomics       Date:  2013-12-08       Impact factor: 5.911

9.  Decreases in plasma A beta 1-40 levels with aging in non-demented elderly with ApoE-epsilon 4 allele.

Authors:  N Pomara; B Shao; T Wisniewski; P D Mehta
Journal:  Neurochem Res       Date:  1998-12       Impact factor: 3.996

10.  Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides.

Authors:  Romain Simon; Marion Girod; Catherine Fonbonne; Arnaud Salvador; Yohann Clément; Pierre Lantéri; Philippe Amouyel; Jean Charles Lambert; Jérôme Lemoine
Journal:  Mol Cell Proteomics       Date:  2012-08-23       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.